Stay updated with breaking news from Affimed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Brokerages expect that Affimed (NASDAQ:AFMD – Get Rating) will post sales of $9.93 million for the current quarter, Zacks reports. Five analysts have provided estimates for Affimed’s earnings, with estimates ranging from $4.42 million to $13.82 million. Affimed posted sales of $14.05 million during the same quarter last year, which suggests a negative year over […]
Equities research analysts predict that Affimed (NASDAQ:AFMD – Get Rating) will post sales of $9.93 million for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Affimed’s earnings, with the highest sales estimate coming in at $13.82 million and the lowest estimate coming in at $4.42 million. Affimed posted sales of […]
Affimed (NASDAQ:AFMD – Get Rating) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 6,560,000 shares, an increase of 39.3% from the March 31st total of 4,710,000 shares. Based on an average trading volume of 1,720,000 shares, the days-to-cover ratio […]
Affimed (NASDAQ:AFMD – Get Rating) – Stock analysts at SVB Leerink reduced their FY2025 earnings per share estimates for Affimed in a report issued on Wednesday, April 27th. SVB Leerink analyst D. Graybosch now expects that the biopharmaceutical company will post earnings of $0.15 per share for the year, down from their prior estimate of […]
Affimed (NASDAQ:AFMD – Get Rating) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 4,710,000 shares, a growth of 27.0% from the March 15th total of 3,710,000 shares. Currently, 4.3% of the shares of the company are short sold. Based […]